Last reviewed · How we verify
Xanax
At a glance
| Generic name | Xanax |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Target | Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Anxiety
- Generalized anxiety disorder
- Mixed anxiety and depressive disorder
- Panic disorder
Common side effects
- Drowsiness
- Fatigue and Tiredness
- Impaired Coordination
- Irritability
- Memory Impairment
- Increased appetite
- Cognitive Disorder
- Decreased appetite
- Constipation
- Weight gain
- Weight loss
- Dysarthria
Serious adverse events
- Seizures
- Withdrawal seizures
- Hallucinations
- Jaundice
- Elevated hepatic enzymes
- Elevated bilirubin
- Depersonalization
- Dystonia
- Diplopia
- Hypotension
Key clinical trials
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (PHASE3)
- A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (PHASE3)
- A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (PHASE1)
- Opioid/Benzodiazepine Polydrug Abuse: Aim 3 (PHASE2)
- Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. (NA)
- An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANAX) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction (PHASE4)
- Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety (NA)
- Oral vs IV Sedation for Cataract Surgery in Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xanax CI brief — competitive landscape report
- Xanax updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI